09 Aug 2023
STAAR Surgical Teams Up With Tennessee Titans Quarterback Will Levis On Life Changing Vision Correction Procedure, EVO ICL
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230809191942/en/

The FDA-approved EVO ICL lenses are successful in correcting myopia, which affects distance vision, and myopia with astigmatism, which causes blurred vision at all distances. As a professional athlete, Levis struggled with his eyesight for 12 years, making it difficult to focus solely on the game while depending on his contact lenses. Earlier this year, Levis had EVO lenses implanted by his doctor to upgrade his vision and break free from the daily hassles of contact lenses and eyeglasses. Starting in
“Getting the EVO lenses has been one of the best decisions I’ve made, and I couldn't be more thrilled with the amazing results,” said Levis. “The ability to wake up with sharp, clear vision has been a game-changer. After learning about this cutting-edge technology, choosing EVO to upgrade my vision was an easy decision. As an athlete, I now have the confidence of knowing that my vision won’t be a worry for me and that my contact lenses won’t bother me during a game. I can’t wait to take my EVO vision out on the field this season.”
“As Will was looking at ways to prepare for his first
The EVO procedure involves implanting (or adding) a proprietary, biocompatible, flexible lens made from Collamer® into the eye between the iris (colored part of the eye) and the natural lens to correct/reduce nearsightedness and astigmatism. The entire EVO ICL procedure typically takes about 20–30 minutes. Most patients experience improved vision right after the procedure. The EVO lens can permanently correct vision without removing corneal tissue and, if desired, is removable by a doctor for added peace of mind. EVO ICL gives the patient flexibility for the future, while also helping to eliminate dependency on glasses and contact lenses now.
Although the EVO ICL lens is new to the U.S. market, it has been approved, marketed and successfully implanted by ophthalmologists throughout
For more information about EVO Implantable Collamer® Lenses, please visit https://evoicl.com.
References
- Martinez-Plazs E, Lopez-Miguel A, Lopez-De La Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226: 117–125.
-
Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the
United States Food and Drug Administration clinical trial. Clinical Ophthalmology. 2022;16:1541-53. - Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016 Jun 29;10:1209-1215.
- Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-1263.
-
Naves,
J. Carracedo ,G. Cacho-Babillo , I. Diadenosine Nucleotid Measurements as Dry-Eye Score in Patients After LASIK and ICL Surgery. Presented atAmerican Society of Cataract and Refractive Surgery (ASCRS) 2012. - Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clinical Ophthalmology 2018: 12: 2427–2438.
About
STAAR, which has been dedicated solely to ophthalmic surgery for over 40 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR’s lens used in refractive surgery is called an Implantable Collamer® Lens or “ICL”, which includes the EVO Visian ICL™ product line. More than 2,000,000 Visian® ICLs have been sold to date and STAAR markets these lenses in over 75 countries. To learn more about the ICL go to: www.evoicl.com. Headquartered in
Safe Harbor
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: product safety, effectiveness, or performance for any particular patient, and any statements of assumptions underlying any of the foregoing. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks factors set forth in the Company’s Annual Report on Form 10-K for the year ended
Important Safety Information for EVO ICL
The EVO Visian ICL lens is intended to correct/reduce nearsightedness between -3.0 D up to -20.0 D and treat astigmatism from 1.0 D to 4.0
For additional information with potential benefits, risks and complications please visit evoicl.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230809191942/en/
[email protected]
Source: